X4 Pharmaceuticals announced the completion of a public offering, raising $155.3 million through 52.8 million shares sold.
Quiver AI Summary
X4 Pharmaceuticals announced the successful completion of its underwritten public offering of 52,844,000 shares of common stock, including the exercise of additional shares by underwriters, generating approximately $155.3 million in gross proceeds. Shares were priced at $2.90 each, with an option for certain investors to purchase pre-funded warrants at $2.899 each, exercisable immediately at a price of $0.001 per share. This offering increases X4's total shares outstanding to 79,214,708. The offering was managed by Leerink Partners, Stifel, and Guggenheim Securities, with the securities registered under a previously effective shelf registration statement. X4 continues to focus on developing therapies for rare hematology diseases, including its orally available CXCR4 antagonist, mavorixafor, currently marketed in the U.S. as XOLREMDI®.
Potential Positives
- X4 Pharmaceuticals raised approximately $155.3 million in gross proceeds from its underwritten public offering, providing significant capital for further development of its therapies.
- The offering included the full exercise of the underwriters' option to purchase additional shares, indicating strong demand for the company’s stock.
- The company is actively developing and commercializing innovative therapies for rare hematology diseases, enhancing its market position and potential for future growth.
- X4 is conducting a pivotal Phase 3 clinical trial (4WARD) for its drug mavorixafor, advancing its product pipeline and addressing significant unmet medical needs.
Potential Negatives
- The public offering of shares may dilute existing shareholders' equity, leading to potential concerns about the company's stock value.
- The nature of the financing through underwritten public offerings can signal to investors that the company might be in need of cash, which can be interpreted as a negative indicator of financial stability.
- The exercise of pre-funded warrants at a very low price could further increase dilution and may raise concerns about valuation among existing shareholders.
FAQ
What was the purpose of X4 Pharmaceuticals' recent public offering?
X4 Pharmaceuticals closed a public offering to raise approximately $155.3 million for its operations and drug development.
How many shares were offered in the public offering?
The public offering included a total of 52,844,000 shares of common stock.
Who were the underwriters for the offering?
Leerink Partners, Stifel, and Guggenheim Securities acted as joint bookrunning managers for the offering.
What are pre-funded warrants in this offering?
The offering included pre-funded warrants to purchase 700,000 shares at an exercise price of $0.001 per share.
What is mavorixafor and its significance for X4?
Mavorixafor is an innovative CXCR4 antagonist marketed as XOLREMDI®, targeting rare hematology diseases with significant unmet needs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XFOR Insider Trading Activity
$XFOR insiders have traded $XFOR stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $XFOR stock by insiders over the last 6 months:
- ADAM R CRAIG (Executive Chairman) purchased 86,206 shares for an estimated $249,997
- MARK BALDRY (Chief Commercial Officer) purchased 1,032 shares for an estimated $2,561
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$XFOR Hedge Fund Activity
We have seen 0 institutional investors add shares of $XFOR stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ACORN CAPITAL ADVISORS, LLC removed 89,958 shares (-36.9%) from their portfolio in Q2 2025, for an estimated $170,920
- NISA INVESTMENT ADVISORS, LLC removed 139 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $475
- NEA MANAGEMENT COMPANY, LLC removed 1 shares (-0.0%) from their portfolio in Q2 2025, for an estimated $1
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$XFOR Analyst Ratings
Wall Street analysts have issued reports on $XFOR in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 08/29/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/02/2025
To track analyst ratings and price targets for $XFOR, check out Quiver Quantitative's $XFOR forecast page.
$XFOR Price Targets
Multiple analysts have issued price targets for $XFOR recently. We have seen 2 analysts offer price targets for $XFOR in the last 6 months, with a median target of $6.25.
Here are some recent targets:
- Stephen Willey from Stifel set a target price of $9.0 on 08/29/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $3.5 on 08/13/2025
Full Release
BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the closing of its previously announced underwritten public offering of 52,844,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 6,984,000 additional shares, at a public offering price per share of $2.90 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 shares of its common stock at a public offering price of $2.899 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to X4 from the offering were approximately $155.3 million before deducting underwriting discounts and commissions and other offering expenses payable by X4. The total shares outstanding after giving effect to the offering was 79,214,708. All of the securities were offered by X4.
Leerink Partners, Stifel and Guggenheim Securities acted as joint bookrunning managers for the offering.
A shelf registration statement relating to these securities was filed with the Securities and Exchange Commission (SEC) on August 14, 2023 and became effective on August 24, 2023. This offering was made only by means of a written prospectus, including a prospectus supplement, forming a part of the effective registration statement. A copy of the final prospectus supplement and the accompanying prospectus relating to the offering have been filed with the SEC, are available on the SEC’s website at www.sec.gov and may be obtained from: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525 ext. 6105, or by emailing [email protected]; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720 or by emailing [email protected]; or Guggenheim Securities, LLC at 330 Madison Avenue, 8th Floor, New York, NY 10017, Attention: Equity Syndicate Department, by telephone at (212) 518-9544, or by email at [email protected].
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The Company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts.
X4 Investor Contact:
